More people are now starting treatment with Eli Lilly's Zepbound than Wegovy in the US
Prescription figures show that Eli Lilly’s obesity drug Zepbound is now prescribed to more new patients in the US than Novo Nordisk’s Wegovy.
by MARKETWIRE
Novo Nordisk’s super-seller Wegovy was overtaken last week by Eli Lilly’s challenger Zepbound in terms of the number of new prescriptions written. This is the first time this has happened, reports Reuters.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
